The neurobiology of placebo analgesia: From endogenous opioids to cholecystokinin

Progress in Neurobiology

Volumn 52, Issue 2, 1997, Pages 109-125

  Benedetti, Fabrizio ^a,b   Amanzio, Martina ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; ENDORPHIN; NALOXONE; OPIATE AGONIST; PLACEBO; PROGLUMIDE;

ANALGESIA; ANXIETY; COGNITION; CONDITIONING; HUMAN; HYPERALGESIA; NEUROMODULATION; NOCICEPTION; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; REVIEW;

EID: 0031005356     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(97)00006-3     Document Type: Article

References (165)

1. Adams, J. E. (1976) Naloxone reversal of analgesia produced by brain stimulation in the human. Pain 2, 161-166.
2. Affleck, D. C. (1966) The action of a medication and the physician's expectations. Nebraska State Med. J. 51, 331-334.
3. Aletky, P. J. and Carlin, A. S. (1975) Sex differences and placebo effects: motivation as an intervening variable. J. Cons. Clin. Psychol. 43, 278.
4. Baber, N. S., Dourish, C. T. and Hill, D. R. (1989) The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39, 307-328.
5. Barber, J. and Mayer, D. (1977) Evaluation of the efficacy and neural mechanism of a hypnotic analgesia procedure in experimental and clinical dental pain. Pain 4, 41-48.
6. Beck, F. M. (1977) Placebos in dentistry: their profound potential effects. J. Am. Dent. Assoc. 95, 1122-1126.
7. Beecher, H. K. (1952) Experimental pharmacology and measurement of the subjective response. Science 116, 157-162.
8. Beecher, H. K. (1955) The powerful placebo. J. Am. Med. Assoc. 159, 1602-1606.
9. Beecher, H. K. (1960) Increased stress and effectiveness of placebos and "active" drugs. Science 132, 91-92.
10. Beinfeld, M. C. (1983) Cholecystokinin in the central nervous system: a minireview. Neuropeptides 3, 411-427.
11. Benedetti, F. (1996) The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64, 535-543.
12. Benedetti, F. (1997) Cholecystokinin type-A and type-B receptors and their modulation of opiod analgesia. News Physiol. Sci. (in press).
13. Benedetti, K., Amanzio, M. and Maggi, G. (1995) Potentiation of placebo analgesia by proglumide. Lancet 346, 1231.
14. Benedetti, F., Amanzio, M., Casadio, C., Oliaro, A. and Maggi, G. (1997) Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain (in press).
15. Berger, P. A., Akil, H., Watson, S. J. and Barchas, J. (1982) Behavioral pharmacology of the endorphins. Ann. Rev. Med. 33, 397-415.
16. Besse, D., Lombard, M. C., Zajac, J. M., Roques, B. P. and Besson, J. M. (1990) Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 521, 15-22.
17. Besson, J. M. and Chaouch, A. (1987) Peripheral and spinal mechanisms of nociception. Physiol. Rev. 67, 67-186.
18. Bonica, J. J. (Ed.) (1990) The Management of Pain. Lea and Fehiger: Edinburgh, U.K.
19. Brewer, W. F. (1974) There is no convincing evidence for operant or classical conditioning in adult humans. In: Cognition and the Symbolic Process, pp. 1-42. Eds W. B. Weimer and D. S. Palermo. Wiley: New York.
20. Buckalew, L. W. (1969) The placebo effect in the 60s: status and direction. Southern J. Educat. Res. 3, 119-124.
21. Buckalew, L. W. (1972) An analysis of experimental components in a placebo effect. Psychol. Rec. 22, 113-119.
22. Buckalew, L. W. and Coffield, K. E. (1982a) Drug expectations associated with perceptual characteristics: ethnic factors. Percept. Motor Skills 55, 915-918.
23. Buckalew, L. W. and Coffield, K. E. (1982b) An investigation of drug expectancy as a function of capsule color and size preparation form. J. Clin. Psychopharmacol. 2, 245-248.
24. Buckalew, L. W. and Ross, S. (1981) Relationship of perceptual characteristics to placebo efficacy. Psychol. Rep. 49, 955-961.
25. Buckalew, L. W., Ross, S. and Starr, B. J. (1981) Nonspecific factors in drug effects: placebo personality. Psychol. Rep. 48, 3-8.
26. Calvey, T. N. and Williams, N. E. (1991) Principles and Practice of Pharmacology for Anaesthetists. Blackwell: Oxford.
27. Cannon, W. B. (1942) Voodoo death. Am. Anthropol. 44, 169-181.
28. Chapman, C. R. and Benedetti, C. (1977) Analgesia following transcutaneous electric stimulation and its partial reversal by narcotic antagonist. Life Sci. 21, 1645-1648.
29. Chiodo, L. A. and Bunney, B. S. (1983) Proglumide: selective antagonism of excitatory effects of cholecystokinin in central nervous system. Science 219, 1449-1451.
30. Cobb, L. A., Thomas, G. I., Dillard, D. H., Merendino, K. A. and Bruce, R. A. (1959) An evaluation of internal mammary artery ligation by double blind technique. New Eng. J. Med. 260, 1115-1118.
31. Crawley, J. N. and Corwin, R. L. (1994) Biological actions of cholecystokinin. Peptides 15, 731-755.
32. Diehl, H. S. (1933) Medical treatment of the common cold. J. Am. Med. Assoc. 101, 2042-2045.
33. Dimond, E. G., Kittle, C. F. and Crockett, J. E. (1958) Evaluation of internal mammary ligation and sham procedure in angina pectoris. Circulation 18, 712-713.
34. Dinnerstein, A. J. and Halm, J. (1970) Modification of placebo effects by means of drugs: effects of aspirin and placebos on self-rated moods. J. Abnorm. Psychol. 75, 308-314.
35. Dourish, C. T., Hawley, D. and Iversen, S. D. (1988) Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364718. Eur. J. Pharmacol. 147, 469-472.
36. Dourish, C. T., O'Neill, M. F., Coughlan, J., Kitchener, S. J., Hawley, D. and Iversen, S. D. (1990) The selective CCK-B receptor antagonist L-365/260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176, 35-44.
37. Duggan, A. W. and North, R. A. (1984) Electrophysiology of opioids. Pharmacol. Rev. 35, 219-281.
38. El-Sobky, A., Dostrovsky, J. O. and Wall, P. D. (1976) Lack of effect of naloxone on pain perception in humans. Nature 263, 783-784.
39. Engel, G. (1971) Sudden and rapid death during psychological stress: folklore or folkwisdom?. Ann. Int. Med. 74, 771-782.
40. Evans, F. J. (1977) The placebo control of pain: A paradigm for investigating non-specific effects in psychotherapy. In: Psychiatry: Areas of Promise and Advancement, pp. 249-271. Eds J. P. Brady, J. Mendels, W. R. Reiger and M. T. Orne. Plenum: New York.
41. Evans, F. J. (1985) Expectancy, therapeutic instructions, and the placebo response. In: Placebo: Theory, Research, and Mechanisms, pp. 215-228. Eds L. White, B. Tursky and G. E. Schwartz. Guilford: New York.
42. Faris, P. L., Komisaruk, B. R., Watkins, L. R. and Mayer, D. J. (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219, 310-312.
43. Fields, H. L. and Levine, J. D. (1984) Placebo analgesia - a role for endorphins?. Trends Neurosci. 7, 271-273.
44. Fisher, S. (1970) Nonspecific factors as determinants of behavioral response to drugs. In: Clinical Handbook of Psychopharmacology. Eds A. Di Mascio and R. I. Shader. Science House: New York.
45. Frederickson, R. C. and Geary, L. E. (1982) Endogenous opioid peptides: review of physiological, pharmacological and clinical aspects. Progr. Neurobiol. 19, 19-69.
46. Frid, M. and Singer, G. (1979) Hypnotic analgesia in conditions of stress is partially reversed by naloxone. Psychopharmacology 63, 211-215.
47. Frid, M., Singer, G. and Rana, C. (1979) Interactions between personal expectations and naloxone: effects on tolerance to ischemic pain. Psychopharmacology 65, 225-231.
48. Gall, C., Lauterborn, J., Burks, D. and Seroogy, K. (1987) Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res. 403, 403-408.
49. Gelbman, F. (1967) The physician, the placebo and the placebo effect. Ohio State Med. J. 63, 1459-1461.
50. Gelfand, S., Ullmann, L. P. and Krasner, L. I. (1963) The placebo response: an experimental approach. J. Nerv. Ment. Dis. 136, 379-387.
51. Ghilardi, J. R., Allen, C. J., Vigna, S. R., McVey, D. C. and Mantyh, P. W. (1992) Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J. Neurosci. 12, 4854-4866.
52. Gibbins, I. L., Furness, J. B. and Costa, M. (1987) Pathway-specific patterns of coexistence of substance P, calcitonin, gene-related peptide, cholecystokinin and dynorphin in neurons of the dorsal root ganglia of the guinea pig. Cell Tissue Res. 248, 417-437.
53. Gleidman, L. H., Gantt, W. H. and Teitelbaum, H. A. (1957) Some implications of conditional reflex studies for placebo research. Am. J. Psychiat. 113, 1103-1107.
54. Goldstein, A. and Grevert, P. (1978) Placebo analgesia, endorphins, and naloxone. Lancet 2, 1385.
55. Goldstein, A. and Hilgard, E. R. (1975) Failure of the opiate antagonist naloxone to modify hypnotic analgesia, Proc. Natl. Acad. Sci. U.S.A. 72, 2041-2043.
56. Gracely, R. H., Dubner, R., Wolskee, P. J. and Deeter, W. R. (1983) Placebo and naloxone can alter postsurgical pain by separate mechanisms. Nature 306, 264-265.
57. Gracely, R. H., McGrath, P. and Dubner, R. (1978) Validity and sensitivity of ratio scales of sensory and affective verbal pain descriptors: manipulation of affect by diazepam. Pain 5, 19-29.
58. Gracely, R. H., McGrath, P. and Dubner, R. (1979) Fentanyl reduces the intensity but not the unpleasantness of painful tooth sensations. Science 203, 1261-1263.
59. Grevert, P., Albert, L. H. and Goldstein, A. (1983) Partial antagonism of placebo analgesia by naloxone. Pain 16, 129-143.
60. Grevert, P. and Goldstein, A. (1977) Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc. Natl. Acad. Sci. U.S.A. 74, 1291-1294.
61. Grevert, P. and Goldstein, A. (1978) Endorphins: naloxone fails to alter experimental pain or mood in humans. Science 199, 1093-1095.
62. Grevert, P. and Goldstein, A. (1985) Placebo analgesia, naloxone, and the role of endogenous opioids. In: Placebo: Theory, Research, and Mechanisms, pp. 332-350. Eds L. White, B. Tursky and G. E. Schwartz. Guilford: New York.
63. Hahn, R. A. (1985) A sociocultural model of illness and healing. In: Placebo: Theory, Research, and Mechanisms, pp. 167-195. Eds L. White, B. Tursky and G. E. Schwartz. Guilford: New York.
64. Hahne, W. F., Jensen, R. T., Lemp, G. F. and Gardner, J. D. (1981) Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 78, 6304-6308.
65. Haier, R. J., Quaid, K. and Mills, J. S. C. (1981) Naloxone alters pain perception after jogging. Psychiat. Res. 5, 231-232.
66. Han, J. S., Ding, X. Z. and Fan, S. G. (1986) Cholecystokinin octapeptide (CCK-8): antagonism to electroacupuncture analgesia and a possible role in electroacupuncture tolerance. Pain 27, 101-115.
67. Harro, J., Pold, M. and Vasar, E. (1990) Anxiogenic-like action of caerulein, a CCK-8 receptor agonist in the mouse: influence of acute and subchronic diazepam treatment. Naunyn-Schmied. Arch. Pharmacol. 341, 62-67.
68. Harro, J. and Vasar, E. (1991) Evidence that CCK-B receptors mediate the regulation of exploratory behaviour in the rat. Eur. J. Pharmacol. 193, 379-381.
69. Hashish, I., Hai, H. K., Harvey, W., Feinmann, C. and Harris, M. (1988) Reduction of postoperative pain and swelling by ultrasound treatment: a placebo effect. Pain 33, 303-311.
70. Herrnstein, R. J. (1962) Placebo effect in the rat. Science 138, 677-678.
71. 3H-MK-329. J. Neurosci. 10, 1070-1081.
72. Holaday, J. W., Long, J. B. and Tortella, F. C. (1989) Opioids and stress: effects upon nociception, behavior, and autonomie function following electroconvulsive shock, circulatory shock, or central nervous system injury. In: Neuropeptides and Stress, pp. 256-275. Eds Y. Taché, J. E. Morley and M. R. Brown. Springer: Berlin.
73. Honigfeld, G. (1964a) Nonspecific factors in treatment: I. Review of placebo reactions and placebo reactors. Dis. Nerv. Sys. 25, 145-156.
74. Honigfeld, G. (1964b) Nonspecific factors in treatment: II. Review of social-psychological factors. Dis. Nerv. Sys. 25, 225-239.
75. Hosobuchi, Y., Adams, J. E. and Linchitz, R. (1977) Pain relief by electrical stimulation of the central grey matter in humans and its reversal by naloxone. Science 197, 183-186.
76. Hughes, J., Hunter, J. C. and Woodruff, G. N. (1991) Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists. Neuropeptides 19S, 85-89.
77. Hurst, P. M., Weidner, M. F., Radlow, R. and Ross, S. (1973) Drugs and placebos: drug guessing by normal volunteers. Psychol. Rep. 33, 683-694.
78. Itoh, S., Katsuura, G. and Maeda, Y. (1982) Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur. J. Pharmacol. 80, 421-425.
79. Jacobs, K. W. and Nordan, F. M. (1979) Classification of placebo drugs: effect of color. Percept. Motor Skills 49, 367-372.
80. Jellinek, E. M. (1946) Clinical tests on comparative effectiveness of analgesic drugs. Biomet. Bull. 2, 87-91.
81. Jospe, M. (1978) The placebo effect in healing. In: Lexington Books. Lexington: Massachusetts.
82. Katsuura, G. and Itoh, S. (1985) Potentiation of beta-endorphin effects by proglumide in rats. Eur. J. Pharmacol. 107, 363-366.
83. Kissel, P. and Barrucand, D. (1974) Placébos et Effet - Placébo en Médecine. Masson: Paris.
84. Korczyn, A. (1978) Mechanism of placebo analgesia. Lancet 2, 1304-1305.
85. Kosterlitz, H. W. (1985) Opioid peptides and their receptors. Proc. R. Soc. Lond. 225, 27-40.
86. Lasagna, L. (1965) Drug interaction in the field of analgesic drugs. Proc. R. Soc. Med. 58, 978-983.
87. Lasagna, L., Mosteller, F., von Felsinger, J. M. and Beecher, H. K. (1954) A study of the placebo response. Am. J. Med. 16, 770-779.
88. Lavigne, G. J., Hargreaves, K. M., Schmidt, E. A. and Dionne, R. A. (1989) Proglumide potentiates morphine analgesia for acute postsurgical pain. Clin. Pharmacol. Ther. 45, 666-673.
89. Lavigne, G. J., Millington, W. R. and Mueller, G. P. (1992) The CCK-A and CCK-B receptor antagonists, devazepide and L-365 260, enhance morphine antinociception only in nonacclimated rats exposed to a novel environment. Neuropeptides 21, 119-129.
90. Lehmann, K. A., Schlusener, M. and Arabatsis, P. (1989) Failure of proglumide, a cholecystokinin antagonist, to potentiate clinical morphine analgesia. A randomised double-blind postoperative study using patient-controlled analgesia (PCA). Anesth. Analg. 68, 51-56.
91. Levine, J. D. and Gordon, N. C. (1984) Influence of the method of drug administration on analgesic response. Nature 312, 755-756.
92. Levine, J. D., Gordon, N. C. and Fields, H. L. (1978) The mechanism of placebo analgesia. Lancet 2, 654-657.
93. Levine, J. D., Gordon, N. C. and Fields, H. L. (1979) Naloxone dose dependency produces analgesia and hyperalgesia in postoperative pain. Nature 278, 740-741.
94. Lewis, G. (1977) Fear of sorcery and the problem of death by suggestion. In: The Anthropology of the Body. Ed. J. Blacking. Academic Press: New York.
95. Lex, B. W. (1974) Voodoo death; new thoughts on an old explanation. Am. Anthropol. 76, 818-823.
96. Liberman, R. (1964) An experimental study of the placebo response under three different situations of pain. J. Psychiat. Res. 2, 233-246.
97. Lombard, M. C. and Besson, J. M. (1989) Attempts to gauge the relative importance of pre- and postsynaptic effects of morphine on the transmission of noxious messages in the dorsal horn of the rat spinal cord. Pain 37, 335-345.
98. Lyerly, S. B., Ross, S., Krugman, A. D. and Clyde, D. J. (1964) Drugs and placebos: the effects of instructions upon performance and mood under amphetamine sulphate and chloral hydrate. J. Abnorm. Soc. Psychol. 68, 321-327.
99. Magnuson, D. S. K. and Dickenson, A. H. (1991) Lamina-specific effects of morphine and naloxone in dorsal horn of rat spinal cord in vitro. J. Neurophysiol. 66, 1941-1950.
100. Mailleux, P. and Vanderhaeghen, J. J. (1990) Cholecystokinin receptors of A type in the human dorsal medulla oblongata and meningiomas, and of B type in small cell lung carcinomas. Neurosci. Lett. 117, 243-247.
101. Maldonado, R., Derrien, M., Noble, F. and Roques, B. P. (1993) Association of a peptidase inhibitor and a CCK-B antagonist strongly potentiates antinociception mediated by endogenous enkephalins. NeuroReport 7, 947-950.
102. Mayer, D. J., Price, D. D. and Rafii, A. (1977) Antagonism of acupuncture analgesia in man by the narcotic antagonist naloxone. Brain Res. 121, 368-372.
103. McGlashan, T. H., Evans, F. J. and Orne, M. T. (1969) The nature of hypnotic analgesia and placebo response to experimental pain. Psychosom. Med. 31, 227-246.
104. Moran, T. H., Robinson, P., Goldrich, M. S. and McHugh, P. R. (1986) Two brain Cholecystokinin receptors: implications for behavioral actions. Brain Res. 362, 175-179.
105. Morris, L. A. and O'Neal, E. C. (1974) Drug-name familiarity and the placebo effect. J. Clin. Psychol. 30, 280-282.
106. Noble, F., Derrien, M. and Roques, B. P. (1993) Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol. 109, 1064-1070.
107. North, R. A. (1989) Drug receptors and the inhibition of nerve cells. Br. J. Pharmacol. 98, 13-28.
108. Ossipov, M. H., Kovelowski, C. J. and Porreca, F. (1995) The increase in potency produced by carrageenan-induced inflammation is blocked by naltrindole, a selective delta opioid antagonist. Neurosci. Lett. 184, 173-176.
109. Park, G. R. and Gempeler, F. (1993) Sedation and Analgesia. Saunders Company: London.
110. Paterson, S. J., Robson, L. E. and Kosterlitz, H. W. (1983) Classification of opioid receptors. Br. Med. Bull. 39, 31-36.
111. Price, D. D., Von der Gruen, A., Miller, J., Rafii, A. and Price, C. (1985) Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist. Anesth. Analg. 64, 801-806.
112. Rawlinson Crenshaw, M. (1985) Truth-telling and paternalism in the clinic: philosophical reflections on the use of placebos in medical practice. In: Placebo: Theory, Research, and Mechanisms, pp. 403-418. Eds L. White, B. Tursky and G. E. Schwartz. Guilford: New York.
113. Ray, O. (1978) Drugs, Society and Human Behavior. C. V. Mosby: St Louis.
114. Rosenthal, D. and Frank, J. (1956) Psychotherapy and the placebo effect. Psychol. Bull. 53, 294-302.
115. Ross, S. and Buckalew, L. W. (1985) Placebo agentry: assessment of drug and placebo effects. In: Placebo: Theory, Research, and Mechanisms, pp. 67-82. Eds L. White, B. Tursky and G. E. Schwartz. Guilford: New York.
116. Ross, S., Krugman, A. D., Lyerly, S. B. and Clyde, B. J. (1962) Drugs and placebos: a model design. Psychol. Rep. 10, 383-392.
117. Rovati, A. L. (1968) The relationship between chemical structure of a new dicarboxylic amino-acid derivate and antigastrin activity in the rat. Br. J. Pharmacol. 34, 667P.
118. Rovati, A. L. (1976) Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents. Scand. J. Gastroenterol. 11, 113.
119. Salar, G. and Iob, I. (1978) Modification de l'action analgesique de l'électrothérapie transcutanée après traitment avec naloxone. Neurochirurgie 24, 415-417.
120. Sawynok, J., Pinsky, C. and LaBella, F. S. (1979) Minireview on the specificity of naloxone as an opiate antagonist. Life Sci. 25, 1621-1632.
121. Schachter, S. and Singer, J. E. (1962) Cognitive, social and physiological determinants of emotional states. Psychol. Rev. 69, 379-399.
122. Schull, J., Kaplan, H. and O'Brien, C. P. (1981) Naloxone can alter experimental pain and mood in humans. Physiol. Psychol. 9, 245-250.
123. Shapiro, A. K. (1960) A contribution to the history of the placebo effect. Behav. Sci. 5, 109-135.
124. Siegel, S. (1985) Drug-anticipatory responses in animals. In: Placebo: Theory, Research, and Mechanisms, pp. 288-305. Eds L. White, B. Tursky and G. E. Schwartz. Guilford: New York.
125. Sjolund, B. and Eriksson, M. (1976) Electro-acupuncture and endogenous morphines. Lancet 2, 1085.
126. Skrabanek, P. (1978) Naloxone and placebo. Lancet 2, 791.
127. Sleisenger, M. H. (1958) The double-blind test in the evaluation of the therapeutic effect of drugs. Am. J. Dig. Dis. 3, 411-415.
128. Smith, G. M., Egbert, L. D., Markowitz, R. A., Mosteller, F. and Beecher, H. K. (1966) An experimental pain method sensitive to morphine in man: the submaximum effort tourniquet technique. J. Pharmacol. Exp. Ther. 154, 324-332.
129. Smith, G. M., Lowenstein, E., Hubbard, J. H. and Beecher, H. K. (1972) Experimental pain produced by the submaximum effort tourniquet technique: further evidence of validity. J. Pharmacol. Exp. Ther. 163, 468-474.
130. Stanfa, L. C., Dickenson, A. H., Xu, X.-J. and Wiesenfeld-Hallin, Z. (1994) Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol. Sci. 15, 65-66.
131. Stein, C., Comisel, K., Haimerl, E., Yassouridis, A., Lehrberger, K., Herz, A. and Peter, K. (1991) Analgesic effect of intraarticular morphine after arthroscopic knee surgery. New Eng. J. Med. 325, 1123-1126.
132. Stein, C., Gramsch, C. and Herz, A. (1990) Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J. Neurosci. 10, 1292-1298.
133. Stein, C., Millan, M. J., Shippenberg, T. S., Peter, K. and Herz, A. (1989) Peripheral opioid receptors mediating antinociception in inflammation: evidence for involvement of mu, delta and kappa receptors. J. Pharmacol. Exp. Ther., 248, 1269-1275.
134. Stengaard-Pedersen, K. and Larsson, L. I. (1981) Localization and opiate receptor binding of enkephalin, CCK and ACTH/ beta-endorphin in the rat central nervous system. Peptides 1, 3-19.
135. Suberg, S. N., Culhane, E. S., Carstens, E. and Watkins, L. R. (1985) Behavioral and electrophysiological investigations of opiate/cholecystokinin interactions. In: Advances in Pain Research and Therapy, Vol. 9, pp. 541-553. Eds H. L. Fields, R. Dubner and F. Cervero. Raven Press: New York.
136. Taché, Y., Morley, J. E. and Brown, M. R. (1989) Neuropeptides and Stress. Springer: Berlin.
137. Terenius, L. (1989) Opioid receptors and their ligands. In: Neuropeptides and Stress, pp. 247-255. Eds Y. Taché, J. E. Morley and M. R. Brown. Springer: Berlin.
138. Tetreault, L. and Bordeleau, J. M. (1970) On the usefulness of placebo and of the double-blind technique for the evaluation of psychotropic drugs. Encephale 59, 5-24.
139. Trivedi, B. K. (1994) Cholecystokinin receptors antagonists: current status. Curr. Med. Chem. 1, 313-327.
140. Tyler, D. B. (1946) The influence of a placebo and medication on motion sickness. Am. J. Physiol. 146, 458-466.
141. Valverde, O., Maldonado, R., Fournie-Zaluski, M. C. and Roques, B. P. (1994) Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Ther. 270, 77-88.
142. Van Megen, H. J. G. M., Den Boer, J. A. and Westenberg, H. G. M. (1994) On the significance of cholecystokinin receptors in panic disorder. Progr. Neuro-Psychopharmacol. Biol. Psychiat. 18, 1235-1246.
143. Vanderah, T. W., Lai, J., Yamamura, H. I. and Porreca, F. (1994) Antisense oligonucleotide to the CCK-B receptor produces naltrindole- and (Leu5) enkephalin antiserum-sensitive enhancement of morphine antinociception. NeuroReport 5, 2601-2605.
144. Vanderhaegen, J. J., Signeau, J. C. and Gepts, W. (1975) New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257, 604.
145. Volavka, J., Bauman, J., Pevnick, J., Reker, D., James, B. and Cho, D. (1980) Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology 5, 225-234.
146. Voudouris, N. J., Peck, C. L. and Coleman, G. (1989) Conditioned response models of placebo phenomena: further support. Pain 38, 109-116.
147. Voudouris, N. J., Peck, C. L. and Coleman, G. (1990) The role of conditioning and verbal expectancy in the placebo response. Pain 43, 121-128.
148. Wall, P. D. (1979) On the relation of injury to pain. Pain 6, 253-264.
149. Wall, P. D. (1992) The placebo effect: an unpopular topic. Pain 51, 1-3.
150. Wall, P. D. (1993) Pain and the placebo response. In: Experimental and Theoretical Studies of Consciousness, pp. 187-216. Ciba Foundation Symposium 174. Wiley: New York.
151. Wang, J., Ren, M. and Han, J. (1992) Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effects of cholecystokinin octapeptide. Peptides 13, 947-951.
152. Watkins, L. R., Kinscheck, I. B., Kaufmann, E. F. S., Miller, J., Frenk, H. and Mayer, D. J. (1985a) Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res. 327, 181-190.
153. Watkins, L. R., Kinscheck, I. B. and Mayer, D. J. (1985b) Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res. 327, 169-180.
154. White, L., Tursky, B. and Schwarz, G. E. (Eds) (1985) Placebo: Theory, Research, and Mechanisms. Guilford: New York.
155. Wickramasekera, I. (1980) A conditioned response model of the placebo effect: predictions from the model. Biofeedback Self-Reg. 5, 5-18.
156. Wickramasekera, I. (1985) A conditioned response model of the placebo effect: predictions from the model. In: Placebo: Theory, Research, and Mechanisms, pp. 255-287. Eds L. White, B. Tursky and G. E. Schwartz. Guilford: New York.
157. Wiesenfeld-Hallin, Z., Xu, X.-J., Hughes, J., Horwell, D. C. and Hökfelt, T. (1990) PD 134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl. Acad. Sci. U.S.A. 87, 7105-7109.
158. Wolf, S. (1950) Effects of suggestion and conditioning on the action of chemical agents in human subjects: the pharmacology of placebos. J. Clin. Invest. 29, 100-109.
159. Wolf, S. and Pinsky, R. H. (1954) Effects of placebo administration and occurrence of toxic reactions. J. Am. Med. Assoc. 155, 339-341.
160. Woodruff, G. N., Hill, D. R., Boden, P., Pinnock, R., Singh, L. and Hughes, J. (1991) Functional role of brain CCK receptors. Neuropeptides 19S, 45-56.
161. Xu, X.-J., Hökfelt, T., Hughes, J. and Wiesenfeld-Hallin, Z. (1994) The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats. NeuroReport 5, 718-720.
162. Xu, X.-J., Puke, M. J. C., Verge, V. M. K., Wiesenfeld-Hallin, Z., Hughes, J. and Hökfelt, T. (1993) Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci. Lett. 152, 129-132.
163. Yaksh, T. L., Al-Rodhan, N. and Jenson, T. S. (1988) Sites of action of opiates in production of analgesia. In: Progress in Brain Research, pp. 371-394. Eds H. L. Fields and J. M. Besson. Elsevier: Amsterdam.
164. Yaksh, T. L. and Malmberg, A. B. (1994) Interaction of spinal modulatory systems. In: Progress in Pain Research and Management, pp. 151-171. Eds H. L. Fields and J. C. Liebeskind. IASP Press: Seattle.
165. Zhou, Y., Sun, Y. H., Zhang, Z. W. and Han, J. S. (1993) Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCK-B receptor antagonist L-365 260 in rat spinal cord. Eur. J. Pharmacol. 234, 147-154.